LinkBIO accelerates drug discovery by providing advanced aptamer discovery platforms and contract research services. Their proprietary MACE®-SELEX technology enables high-throughput screening and selection of DNA aptamers with precise binding characteristics, reducing the time and resources needed for preclinical research.
Funding
Funding not disclosed
Founders
Product
Problem
The drug discovery process faces significant bottlenecks in identifying and validating novel therapeutic candidates. Traditional screening methods can be time-consuming and may not efficiently identify aptamers with the desired specificity and affinity for target molecules. This limits the pace of therapeutic development for various diseases.
Solution
LinkBIO provides advanced separation technologies and proprietary aptamer discovery platforms to accelerate the identification of novel therapeutic agents. Our core technology, MACE®-SELEX, enables high-throughput screening and selection of DNA aptamers with precise binding characteristics. We offer contract research services that leverage these capabilities to support the development of nucleic acid therapeutics and diagnostic agents. By optimizing the aptamer discovery pipeline, we aim to reduce the time and resources required for preclinical research.
Target Audience
Our primary customers are pharmaceutical companies, biotechnology firms, and academic research institutions engaged in early-stage drug discovery and therapeutic development.
Features
- MACE®-SELEX (Systematic Evolution of Ligands by Exponential Enrichment) platform for high-throughput aptamer discovery.
- Aptamer screening and selection services for identifying molecules with specific binding affinities to target proteins or cells.
- Development of bispecific DNA aptamers for targeted therapeutic applications.
- Proprietary methods for aptamer validation and characterization.
- Collaboration with academic institutions and industry partners to advance drug discovery projects.
- Patent-pending aptamer screening methodologies.